Ustekinumab Shows Promise in Crohn's Disease

Share this content:
Ustekinumab Shows Promise in Crohn's Disease
Ustekinumab Shows Promise in Crohn's Disease

FRIDAY, Nov. 18, 2016 (HealthDay News) -- Patients with moderate-to-severe Crohn's disease who haven't responded to other treatments may benefit from the drug ustekinumab (Stelara), according to a study published in the Nov. 17 issue of the New England Journal of Medicine.

William Sandborn, M.D., a professor of medicine at the University of California, San Diego, and colleagues recruited two groups of patients, one with 741 participants, and the other with 628. These patients hadn't responded to anti-tumor necrosis factor treatment or had unacceptable side effects from it. The study volunteers were randomly assigned to receive either a single intravenous dose of ustekinumab or a placebo. The researchers then took 397 patients who showed a response to ustekinumab and randomly assigned them to receive regular injections of ustekinumab or a placebo every eight weeks or 12 weeks.

The researchers found that after 44 weeks, 53.1 percent of patients receiving ustekinumab injections every eight weeks were in remission. For patients getting ustekinumab every 12 weeks, 48.8 percent were in remission. This compared with 35.9 percent of those receiving a placebo.

Ustekinumab is a monoclonal antibody that blocks the action of the inflammatory agents interleukin-12 and interleukin-23. The drug had been approved for the treatment of psoriasis and is now approved for treating Crohn's disease as well. Ustekinumab was well tolerated and "we did not see increased rates of serious infection or cancer, compared with patients who received placebo," Sandborn told HealthDay.

Several authors disclosed financial ties to pharmaceutical companies, including Janssen Research and Development, which manufactures ustekinumab and funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Post-Deployment Screening Has Limited Benefit in U.K. Military

Post-Deployment Screening Has Limited Benefit in U.K. Military

Screening based on tailored advice does not reduce prevalence of disorders or increase help-seeking

Excess BMI Ups Risk of T1DM in Autoantibody-Positive Relatives

Excess BMI Ups Risk of T1DM in Autoantibody-Positive ...

Increased diabetes progression risk occurred at lower cumulative excess BMI index in children <12

Baricitinib Associated With Significant Improvement in RA

Baricitinib Associated With Significant Improvement in RA

Findings versus placebo, adalimumab in patients non-responsive to methotrexate

is free, fast, and customized just for you!

Already a member?

Sign In Now »